EPOMAX 2000UI BT 10

EPOMAX is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD):

• In hemodialyzed adult and pediatric patients aged 1 to 18 years, and in adult patients on peritoneal dialysis.
• In non-dialyzed adult patients with severe renal anemia accompanied by clinical symptoms.

EPOMAX is also indicated in adults receiving chemotherapy for solid tumors, malignant lymphoma, or multiple myeloma, and at risk of transfusion due to their general condition (e.g. cardiovascular status, pre-existing anemia at the start of chemotherapy) for the treatment of anemia and reduction of transfusion requirements.

In addition, EPOMAX is indicated for adults participating in a delayed autologous transfusion program to increase autologous blood donations. Treatment should only be administered to patients with moderate anemia (hemoglobin concentration between 10 and 13 g/dL [i.e. 6.2 - 8.1 mmol/L], without iron deficiency) when there are few or no blood-saving methods available and a major scheduled surgical intervention requires large amounts of blood (4 units or more in women and 5 units or more in men).

Finally, EPOMAX is indicated in non-iron deficient adults scheduled for major orthopedic surgery and at significant presumed risk of transfusion complications, to reduce exposure to homologous blood transfusions. The use should be reserved for patients with moderate anemia (e.g. hemoglobin concentration between 10 and 13 g/dL) who do not have access to a delayed autologous transfusion program and are expected to experience moderate blood loss (900 to 1800 mL).